On 14 September 2026, the FDA recorded a supplement to abbreviated new drug application ANDA206741 for itraconazole, held by Alembic. An ANDA covers a generic version of an already approved drug, and a supplement typically concerns manufacturing, labelling or packaging changes.
The FDA record gives no details of what changed. There is no new indication and no safety communication. For prescribers, nothing about itraconazole use changes.
The item is relevant in India because Alembic is an Indian manufacturer, and itraconazole is heavily used here for dermatophytosis, often in doses and durations beyond the evidence. That practice issue is unaffected by this filing.
- This is an administrative change to an existing generic, not a new approval or safety warning.
- No change to itraconazole indications, dosing or monitoring follows from it.
- Itraconazole has important interactions via CYP3A4; check before co-prescribing statins, calcium channel blockers or some anticoagulants.
- Absorption of capsules needs food and gastric acid; avoid co-prescribing acid suppressants where possible.
Why it matters
The holder is an Indian manufacturer; the filing does not affect prescribing.
Don't overread it
A licence supplement on a generic is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free